Analysts rate Intellia Therapeutics Inc. (NTLA:NSD) with a Strong Buy rating and a $116 target

STA Research
by: STA Research
Intellia Therapeutics Inc.

Analysts rate Intellia Therapeutics Inc. (NTLA:NSD) with a consensus Strong Buy rating with an average 12-months Intellia stock price target of $166.36 per share.

Credit Suisse recently raised the target on the Intellia’s stock price to $101.

Based on the Intellia Therapeutics Inc. stock forecast from 11 analysts, the average analyst Intellia stock price target is USD 116.36 over the next 12 months. Intellia Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of NTLA stock forecast is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Intellia stock price was USD 60.56Intellia stock price has changed by -3.61% over the past week, -4.59% over the past month and -62.69% over the last year.

About Intellia Therapeutics Inc. (NTLA:NSD):

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

What we like:

High market capitalization

NTLA stock is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

NTLA stock has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.

What we don’t like:

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

Intellia stock price is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

Intellia stock price is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

NTLA stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

NTLA stock has shown below median revenue growth in the previous 5 years compared to its sector

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.